

SUPPLEMENTAL MATERIAL

Supplemental Table 1. Baseline clinical characteristics of patients at DAPT-participating vs. non-participating hospitals.

Characteristic	Patients at DAPT-Participating Hospital (n = 485177)	Patients at Non-Participating Hospital (n = 654755)	Standardized Difference (%)
Age	64.8 ± 12.0	64.6 ± 12.1	1.1
BMI (kg/m ²)	30.0 ± 6.4	30.0 ± 6.5	0.6
Female	32.3	32.8	-1.0
Race/ethnicity			
American Indian or Alaska Native	0.5	0.5	0.2
Asian	1.7	2.5	-5.3
Black	8.4	7.8	2.1
Hispanic	4.0	5.5	-6.7
Native Hawaiian or Other Pacific Islander	0.2	0.2	-0.5
White	88.6	88.2	1.1
No insurance	6.0	6.6	-2.4
Co-morbidities			
Cerebrovascular disease (%)	12.9	11.7	3.7
CHF, current	9.5	9.7	-0.8
CHF, previous	12.3	11.2	3.4
Chronic Lung Disease (%)	15.0	15.1	-0.4
Current/recent smoker	26.6	28.3	-3.6
Diabetes	36.5	35.7	1.7
Not on insulin	23.0	23.0	-0.1
On insulin	13.5	12.7	2.5
GFR (mL/min/1.73 m ²)*	75.7	75.4	0.9
Hypertension (%)	82.8	81.1	4.5
Peripheral vascular disease (%)	13.3	11.9	4.2
Previous MI	30.9	29.1	4.0
Previous procedures			
PCI	42.3	38.9	6.8
CABG	19.9	17.9	5.2
Presentation			
No angina	9.0	9.3	-0.8
Atypical chest pain	2.7	3.2	-2.5
Stable angina	18.8	16.9	5.0
Unstable angina	37.2	36.0	2.6

Non-STEMI	18.0	17.7	0.6
STEMI	14.2	17.0	-7.6

Values are percent or mean \pm standard deviation. Abbreviations: BMI, body mass index;

CABG, coronary artery bypass grafting; CHF, congestive heart failure; GFR, glomerular filtration rate by MDRD equation estimate; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction. *Creatinine was missing in 8% of patients. All other elements had < 2% missing data.

Supplemental Table 2. Procedural characteristics of patients at DAPT-participating vs. non-participating hospitals.

Procedural Characteristic	Patients at DAPT-Participating Hospital (n = 485177)	Patients at Non-Participating Hospital (n = 654755)	Standardized Difference (%)
<i>PCI indication</i>			
Elective	45.8	44.2	3.1
Urgent	38.1	36.9	2.4
Emergent	15.8	18.4	-7.1
Salvage	0.3	0.3	-1.0
<i>Type of stent</i>			
Any DES	69.9	69.5	0.8
BMS only	21.6	21.5	0.1
No stent	8.6	9.0	-1.5
<i>Segment category</i>			
Any LMCA	1.9	1.6	2.8
Proximal LAD	14.4	15.3	-2.7
Arterial graft	0.5	0.5	-0.1
Vein graft	6.4	5.7	2.6
Multi-vessel	14.1	13.2	2.5
Previously treated lesion	11.6	10.6	3.3
Bifurcation lesion	10.4	11.5	-3.6
<i>Discharge medications</i>			
Aspirin	97.2	95.4	9.4
Clopidogrel	84.9	83.9	2.8
Prasugrel*	12.2	11.8	1.3

Values are percent. Abbreviations: DES, drug-eluting stent; LAD, left anterior descending artery; LMCA, left main coronary artery; PCI, percutaneous coronary intervention. *Data on Prasugrel receipt was missing in 5% of patients. All other elements had < 2% missing data.

Supplemental Table 3. Baseline clinical characteristics of patients receiving DES enrolled in the DAPT trial and those eligible to be enrolled in the CathPCI registry, limited to DAPT-participating hospitals.

Characteristic	DAPT US DES Enrolled (n = 21481)	CathPCI DAPT-Eligible DES Patients (n =320943)	Standardized Difference (%)
Age	62.2 ± 10.6	64.4 ± 11.5	-19.9
Female	28.8	32.2	-7.4
Race			
American Indian or Alaska Native	0.4	0.5	-1.1
Asian	1.1	1.8	-6.2
Black	7.1	7.6	-1.7
Hispanic ethnicity	4.4	3.9	-2.5
Native Hawaiian	0.2	0.2	1.1
White	89.4	89.3	0.3
BMI (kg/m²)	30.6 ± 5.9	30.2 ± 6.3	6.5
Co-morbidities			
Smoker	25.5	24.7	1.8
Diabetes	33.8	36.9	-6.4
Not on insulin	22.3	23.4	-2.6
On insulin	11.5	13.5	-6.0
Hypertension	79.1	83.3	-10.8
Peripheral arterial disease	7.3	12.6	-17.8
Prior CHF	6.8	11.0	-14.9
Prior MI	23.8	30.6	-15.4
Prior procedures			
PCI	35.6	44.4	-18.1
CABG	14.5	19.8	-14.2
Presentation			
Non-STEMI	14.6	16.4	-5.0
STEMI	8.6	10.0	-4.6

Values are percent or mean ± standard deviation. Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction.

Supplemental Table 4. Procedural characteristics of patients receiving DES enrolled in the DAPT trial versus DAPT-eligible patients within the CathPCI registry, limited to DAPT-participating hospitals.

Procedural Characteristic	DAPT US DES Enrolled (n = 21483\1)	CathPCI DAPT-Eligible (n = 320943)	Standardized Difference (%)
High Risk Feature			
Left Main	1.5	2.8	-8.9
Proximal LAD	19.0	18.3	1.9
Arterial graft	0.7	0.5	2.3
Vein graft	3.6	5.8	-10.5
Multi-vessel	11.1	15.6	-13.3
Stent Type			
Everolimus	47.7	63.0	-31.3
Zotarolimus	14.7	10.5	12.9
Paclitaxel	21.9	12.5	25.1
Sirolimus	13.1	9.7	10.6
Multiple Types	2.7	4.3	-9.0
Discharge medications			
Aspirin	99.4	98.6	11.9
Clopidogrel	69.2	86.6	-41.8
Prasugrel*	30.7	14.1	39.0
Outcome			
Post-Procedure Length of stay (days, mean \pm SD)	1.3 \pm 1.2	2.7 \pm 3.4	-56.6
Post-Procedure Length of stay (days, median, interquartile range)	1.00 (1.00, 1.00)	2.00 (2.00, 3.00)	-

Values are percent unless otherwise noted. Abbreviations: LAD, left anterior descending; SD, standard deviation. Missing data were < 4% for all elements. *One of the 4 manufacturer-sponsored studies contributing to the DAPT Study mandated treatment with prasugrel after PCI.